aTyr Pharma, Inc. (ATYR) Stock Forecast
ATYR analyst forecast
as of October 18, 2026- Analyst consensus
- Buy 3.67 / 5 from 9 analysts
- Price target
- $2.86 average of analyst targets
- Upside to target
- +1,542.0% from the latest close
- Next earnings
- November 5, 2026 EPS estimate $-0.11
- 52-week range
- $0.17 – $1.05
ATYR analyst ratings
9 analystsNumber of analysts at each rating.
ATYR price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ATYR earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.10 | −$0.12 | −$0.08 | −$0.26 | +61.5% | 7 |
| Current fiscal year (2026) | −$0.41 | −$0.50 | −$0.36 | −$0.80 | +48.6% | 7 |
| Next fiscal year (2027) | −$0.44 | −$0.93 | −$0.16 | −$0.41 | −7.9% | 8 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ATYR revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $0 | $0 | $0 | −100.0% | 8 |
| Current fiscal year (2026) | $0 | $0 | $0 | −100.0% | 8 |
| Next fiscal year (2027) | $0 | $0 | $0 | 0.0% | 8 |
ATYR EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ATYR EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.13 | −$0.14 | −$0.10 | −$0.10 | −$0.10 | −25.0% | 4 up · 0 down |
| Current fiscal year (2026) | −$0.52 | −$0.56 | −$0.41 | −$0.41 | −$0.41 | −21.4% | 4 up · 0 down |
| Next fiscal year (2027) | −$0.58 | −$0.61 | −$0.44 | −$0.44 | −$0.44 | −23.8% | 4 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ATYR earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ATYR beat in 8 of 12.
What analysts expect from ATYR
9 analysts cover aTyr Pharma; their consensus rating is buy (3.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $2.86, 1,542.0% above the latest close of $0.17. Analysts expect earnings of −$0.41 per share for 2026, +48.6% from a year earlier. For 2027 the average estimate is −$0.44 per share. aTyr Pharma beat the EPS estimate in 8 of the last 12 quarters.
Related: ATYR income statement, ATYR key metrics, ATYR chart. See the ATYR stock overview for the latest quote and news.
ATYR forecast FAQ
What is aTyr Pharma's price target?
The average analyst price target for aTyr Pharma is $2.86, 1,542.0% above the latest close of $0.17.
Is aTyr Pharma a buy, hold or sell?
Of 9 analysts covering aTyr Pharma, 2 rate it a strong buy, 2 a buy, 5 a hold, 0 a sell and 0 a strong sell, a consensus of buy. Ratings are opinions, not a recommendation from Quotelinks.
What is aTyr Pharma's EPS forecast?
Analysts forecast −$0.41 per share for 2026 (range −$0.50 to −$0.36); for 2027 the estimate is −$0.44.
When does aTyr Pharma report earnings?
aTyr Pharma is expected to report results for the quarter ending September 30, 2026 on November 5, 2026 after the market closes; the EPS estimate is $-0.11.
Does aTyr Pharma usually beat earnings estimates?
aTyr Pharma reported EPS at or above the analyst estimate in 8 of the last 12 quarters.